Shifting knowledge and attitudes about biosimilars among rheumatologists

Rheumatology Oxford Journal

Fecha de pubicación: 13 de diciembrede 2020

DOI: https://doi.org/10.1093/rheumatology/keaa760

Autor: Jinoos Yazdany

Background: Rising biologic drug costs pose serious, ongoing threats to the health and financial well-being of people with rheumatic diseases in many areas of the world. As drug costs have increased, national healthcare budgets have strained, and some patients face escalating insurance premiums and out-of-pocket costs. In a 2019 study by the American College of Rheumatology, 60% of US patients with rheumatic disease said they had difficulty affording medications although nearly all had insurance.

Leer más